

## Special Issue

# Application of Emerging Technologies in Zebrafish and Mammalian Cancer Models for Disease Characterization and Therapeutic Target Discovery

### Message from the Guest Editors

Cancer research utilizing zebrafish and mammalian models has been instrumental in contributing to our understanding of cellular and molecular mechanisms underlying disease initiation and progression. Zebrafish and mammalian models are also powerful tools in therapeutic target testing and discovery. The emergence of new gene editing, imaging, functional genomics, and single cell technologies has enabled exciting discoveries and new research directions at the basic science and translational levels. This Special Issue of *Cancers* highlights works that apply emerging gene editing, imaging, functional genomics, and single cell technologies in zebrafish or mammalian models to characterize various hallmarks of cancer and identify therapeutic targets in translational settings

---

### Guest Editors

Dr. Eleanor Y. Chen

Department of Laboratory Medicine and Pathology, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195, USA

Dr. Myron Ignatius

Greehey Children's Cancer Research Institute, UT Health Sciences Center, 8403 Floyd Curl Drive, San Antonio, Texas, USA

---

### Deadline for manuscript submissions

closed (20 October 2022)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/67550](https://mdpi.com/si/67550)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)